Nearly 80 million Americans — one out of every four people — are infected with human papillomavirus (HPV). And of those millions, more than 31,000 will be diagnosed with an HPV-related cancer this year. Despite those staggering figures and the availability of a vaccine to prevent the infections that cause these cancers, HPV vaccination remains low in the United States.
Often what kills cancer patients is not the cancer at its original or primary site, but its spread to secondary sites within the body, through a process called metastasis. In the case of breast cancer, the tumor often spreads to the bone, and it is this bone metastasis that results in intense pain and precedes spread to other organs.
Huntsman Cancer Institute announced today that it has been certified to offer both chimeric antigen receptor (CAR) T cell therapies recently approved by the U.S. Food and Drug Administration. The therapies are approved for types of aggressive blood cancers, including B-cell acute lymphoblastic leukemia and non-Hodgkin lymphoma. HCI is one of a few locations nationwide, and the only in the Mountain West, approved to offer these new therapies to adult cancer patients.
Huntsman Cancer Institute (HCI) at the University of Utah (U of U) today announced the opening of the Cancer Population Sciences and Huntsman Center for Health Outcomes and Population Equity (HOPE), a new research and clinical space dedicated to preventing cancer and improving health among underserved populations and improving outcomes in cancer patients. The center recently received $9.7 million from the Patient-Centered Outcomes Research Institute (PCORI) to fund a clinical trial researching new and effective approaches to reduce tobacco use.